Fibroblast growth factor (FGF23) nucleic acids

US7223563B2 · kind B2 · utility

Assignees

• Advanced Research & Technology Institute · US
• Ludwig-Maximilians-Universitat Munchen · DE

Inventors

• Michael Econs · Indianapolis, US
• Ken W. White · Ithaca, US
• Tim Matthias Strom · Munich, DE
• Thomas Meitinger · Munich, DE

Key dates

• Filing date: Jul 10, 2001
• Grant date: May 29, 2007
• Expiry date: Dec 19, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/172
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.